AbbVie, Gubra post obesity data; Regeneron obesity drug succeeds in Chinanews2026-03-09T15:17:36+00:00March 9th, 2026|Endpoints News|
Xenon gets Phase 3 win with epilepsy drug, setting up FDA approval filingnews2026-03-09T15:04:48+00:00March 9th, 2026|Endpoints News|
Hims agrees to limit compounding, ending feud with Novo Nordisknews2026-03-09T14:44:20+00:00March 9th, 2026|Endpoints News|
Bristol Myers says second CELMoD succeeds in Phase 3news2026-03-09T14:33:32+00:00March 9th, 2026|Endpoints News|
Incyte receives CRL over issues at Novo’s Indiana factorynews2026-03-09T13:21:57+00:00March 9th, 2026|Endpoints News|
RNA editing startup Tacit Therapeutics launches with $19M for brain diseasesnews2026-03-09T13:00:55+00:00March 9th, 2026|Endpoints News|
GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfrontnews2026-03-09T10:29:43+00:00March 9th, 2026|Endpoints News|
Roche’s big-hope breast cancer drug fails in crucial first-line trialnews2026-03-09T08:26:14+00:00March 9th, 2026|Endpoints News|
UniQure’s dispute with FDA; Zealand’s obesity readout; China takes on world’s most expensive medicines; and more news2026-03-07T11:00:32+00:00March 7th, 2026|Endpoints News|
Vinay Prasad to exit FDA again, following latest round of controversynews2026-03-06T22:16:03+00:00March 6th, 2026|Endpoints News|
